Cisterna Biologics Analysis: $500K Raised
What is Cisterna Biologics?
Cisterna Biologics supplies RNA products for research, diagnostics, and therapeutic development. Its platform centers on Prime RNA and SPECC, a method for producing mRNA with fewer dsRNA, short-truncated RNA, and long RNA impurities. The company says it can make RNAs from 16 nucleotides to thousands of bases and has shown NSF SBIR Phase I work on selectively purified yeast-engineered mRNA.
Location
6076 Corte del Cedro, Carlsbad, California 92011, United States
Employees
1-10
Founded
2022
Investors
- Y Combinator
- National Science Foundation
Product Features & Capabilities
- dT-purified mRNA, SPECC-purified mRNA, high-quality mRNA for therapeutic applications, advanced mRNA production technology, solutions for mRNA-related impurities
How much Cisterna Biologics raised
1: - $500,000
August 22, 2022Lead Investor: Y Combinator, National Science Foundation
Market Focus
Cisterna Biologics primarily focuses on the biotechnology industry, specifically in the development and production of mRNA-based therapeutics.
Competitors Overview
Cisterna Biologics operates in the mRNA therapeutics market, which has several notable competitors. The main competitors include:
-
Moderna, Inc.
- Overview: Known for its mRNA COVID-19 vaccine, SpikeVax, Moderna is a leader in mRNA technology and has a robust pipeline of mRNA-based therapeutics for various diseases.
- Advantages: Strong financial backing, extensive research and development capabilities, and a well-established reputation in the market.
-
BioNTech SE
- Overview: Another key player in the mRNA space, BioNTech gained prominence with its COVID-19 vaccine developed in partnership with Pfizer.
- Advantages: Innovative approach to mRNA technology, strong partnerships, and a diverse pipeline targeting cancer and infectious diseases.
-
CureVac N.V.
- Overview: Focuses on mRNA-based vaccines and therapeutics, including candidates for COVID-19 and cancer.
- Advantages: Unique mRNA technology that aims to enhance stability and efficacy, although it has faced challenges in clinical trials compared to competitors like Moderna and BioNTech.
-
Alnylam Pharmaceuticals
- Overview: Specializes in RNA interference (RNAi) therapeutics but is also involved in mRNA technology.
- Advantages: Strong focus on rare diseases and a solid pipeline of innovative therapies.
-
Arcturus Therapeutics
- Overview: Develops mRNA therapeutics and vaccines, including a COVID-19 vaccine candidate.
- Advantages: Proprietary LUNAR delivery technology that enhances mRNA delivery and efficacy.
-
Ethris
- Overview: Focuses on mRNA therapeutics for respiratory diseases and vaccines.
- Advantages: Specialized in developing mRNA therapies that target specific diseases, providing a niche focus in the market.
Notable differences between these competitors and Cisterna Biologics include the scale of operations, financial resources, and the breadth of their product pipelines. While Cisterna Biologics emphasizes high-quality mRNA production and addressing production challenges, competitors like Moderna and BioNTech have established themselves with successful products and extensive research capabilities.
See something that needs updating? Suggest edits to this profile.